Immunocore (NASDAQ:IMCR – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Immunocore to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.
Institutional & Insider Ownership
84.5% of Immunocore shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Immunocore and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Immunocore | $400.02 million | -$35.51 million | -82.41 |
| Immunocore Competitors | $722.78 million | $12.25 million | -10.11 |
Immunocore’s peers have higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Immunocore has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Immunocore’s peers have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.
Profitability
This table compares Immunocore and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunocore | -4.20% | -4.54% | -1.66% |
| Immunocore Competitors | -9,054.29% | -198.66% | -30.54% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Immunocore and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunocore | 1 | 4 | 5 | 1 | 2.55 |
| Immunocore Competitors | 9774 | 15035 | 45262 | 1571 | 2.54 |
Immunocore presently has a consensus price target of $55.86, indicating a potential upside of 83.20%. As a group, “Biotechnology” companies have a potential upside of 95.81%. Given Immunocore’s peers higher probable upside, analysts plainly believe Immunocore has less favorable growth aspects than its peers.
Summary
Immunocore peers beat Immunocore on 7 of the 13 factors compared.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
